Last reviewed · How we verify
Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)
The purpose of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine in healthy children aged 6-35 months.
Details
| Lead sponsor | Sinovac Biotech Co., Ltd |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 2340 |
| Start date | Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Nov 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Seasonal Influenza
Interventions
- Quadrivalent influenza vaccine
- Quadrivalent influenza vaccine
- Trivalent influenza vaccine (contains B/Victoria strain)
- Trivalent influenza vaccine (contains B/Yamagata strain)
Countries
China